Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences
CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in Evercore Biotech Diamonds in the Rough Virtual Event, TD Cowen's 6th Annual Oncology Innovation Summit, Jefferies Global Healthcare Conference 2025 and Goldman Sachs 46th Annual Global Healthcare Conference 2025. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
Evercore Biotech Diamonds in the Rough Virtual Event
Fireside Chat: Tuesday, May 27, 2025, at 2:00 p.m. EDT (Virtual)
Presenter: Adrian Gottschalk, President and Chief Executive Officer
TD Cowen's 6th Annual Oncology Innovation Summit
Fireside Chat: Wednesday, May 28, 2025, at 1:30 p.m. EDT (Virtual)
Presenter: Adrian Gottschalk, President and Chief Executive Officer
Jefferies Global Healthcare Conference 2025
Presentation: Thursday, June 5, 2025, at 3:45 p.m. EDT in New York, NY
Presenter: Adrian Gottschalk, President and Chief Executive Officer
Please find a link to the webcast here
Management will also participate in one-on-one meetings
Goldman Sachs 46th Annual Global Healthcare Conference 2025
Presentation: Wednesday, June 11, 2025, at 10:00 a.m. EDT in Miami, Florida
Presenter: Adrian Gottschalk, President and Chief Executive Officer
Management will also participate in one-on-one meetings
A webcast of the presentation can be accessed under 'Events & Presentations' in the Investors section of the Company's website, www.foghorntx.com, and will be available for 30 days.
About Foghorn TherapeuticsFoghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X and LinkedIn.
Contact:Karin Hellsvik, Foghorn Therapeutics Inc. khellsvik@foghorntx.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
27 minutes ago
- Business Insider
Upcoming Stock Splits This Week (June 9 to June 13)
These are the upcoming stock splits for the week of June 9 to June 13, based on TipRanks' Stock Splits Calendar. A stock split is a corporate maneuver that increases the number of shares outstanding by issuing more shares to existing holders, all while keeping the company's total market value unchanged. This lowers the price per share, often making the stock more affordable and potentially more appealing to retail investors. Confident Investing Starts Here: In contrast, a reverse stock split reduces the number of shares by consolidating them, which raises the price per share without affecting the company's valuation. Companies typically turn to this strategy to meet stock exchange requirements – like Nasdaq's minimum price threshold – and avoid delisting. Whether intended to boost investor interest or maintain compliance with exchange rules, these adjustments often serve as key signals for traders tracking a company's strategic direction. Let's take a look at the upcoming stock splits for the week. Nektar Therapeutics (NKTR) – Nektar Therapeutics is a biopharmaceutical company developing novel drug candidates. Following stockholder approval on May 23, the company formalized a 1-for-15 reverse stock split. The split takes effect on June 8, with trading on a split‑adjusted basis beginning June 9. Fangdd Network Group (DUO) – China-based Fangdd is a technology-driven real estate platform. The company confirmed a 16-for-1 reverse share consolidation, effective June 9, aimed at boosting its share price and maintaining compliance with listing standards. Bone Biologics (BBLG) – Bone Biologics develops orthobiologic products for spinal fusion procedures. After gaining shareholder approval on May 30, the company filed for a 1-for-6 reverse stock split, which takes effect on June 10. The goal is to elevate its share price back into compliance with Nasdaq's minimum pricing rules and enhance its appeal to institutional investors. Cero Therapeutics Holdings (CERO) – Cero Therapeutics is a biotech firm developing engineered T-cell immunotherapies for cancer. Following shareholder approval in November and board action on December 25, it enacted a 1-for-100 reverse stock split effective on January 8, consolidating every 100 shares into one. The move aimed to boost the stock above $1.00 and secure compliance with Nasdaq's listing standards. Inuvo, Inc. (INUV) – Inuvo specializes in AI-powered marketing technologies and is gearing up for a 1-for-10 reverse stock split on June 10. The move is designed to lift its share price, restore Nasdaq compliance, and strengthen its financial foundation for future growth. O'Reilly Automotive (ORLY) – O'Reilly Automotive is a specialty retailer of automotive aftermarket parts and accessories. On March 13, the company declared a 15-for-1 forward stock split, with the distribution of additional shares set for June 9 and split-adjusted trading beginning June 10. SaverOne 2014 (SVRE) – Israel-based SaverOne develops driver safety systems that block mobile-device distractions in vehicles. The company executed a 1-for-3 reverse ADS split, effective June 11, adjusting its American Depositary Share ratio to strengthen its Nasdaq standing and enhance market appeal. China Natural Resources, Inc. (CHNR) – China Natural Resources is focused on mining exploration in Inner Mongolia and is working toward picking up Zimbabwe's Williams Minerals lithium mine for up to $1.75 billion. The company executed an 8-for-1 reverse stock split effective June 12 to meet Nasdaq's $1 minimum bid price requirement, converting every eight shares into one to boost its per-share value and comply with listing rules
Yahoo
an hour ago
- Yahoo
Ituran Location and Control Ltd (ITRN) Q1 2025 Earnings Call Highlights: Record Revenue and ...
Revenue: $86.5 million, a 2% increase year-over-year. Subscription Fees Revenue: $62.2 million, a 2% increase year-over-year. Product Revenue: $24.3 million, a 1% increase year-over-year. EBITDA: $23.3 million, 26.9% of revenues, a 4% increase year-over-year. Net Income: $14.6 million, or $0.73 diluted earnings per share, a 12% increase year-over-year. Operating Cash Flow: $15.5 million for the first quarter. Subscriber Base: Increased by 99,000 to 2,508,000. Dividend: $10 million declared for the quarter, representing $0.50 per share. Net Cash: $75.7 million as of March 31, 2025. Warning! GuruFocus has detected 4 Warning Signs with MOV. Release Date: May 28, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Ituran Location and Control Ltd (NASDAQ:ITRN) achieved a significant milestone by surpassing 2.5 million subscribers, driven by a net addition of 99,000 subscribers in the first quarter. The company signed a new telematics service agreement with Stellantis, a major car OEM manufacturer, contributing to the subscriber growth. First-quarter revenues reached a record $86.5 million, marking a 2% increase year-over-year, with a 7% growth in local currency terms. EBITDA for the quarter increased by 4% to $23.3 million, with a 12% growth in local currency terms. Ituran Location and Control Ltd (NASDAQ:ITRN) declared a $10 million dividend for the quarter, reflecting strong profitability and cash flow, with an annualized dividend yield of around 6%. The strengthening of the US dollar negatively impacted financial results when translated from local currencies, particularly affecting revenues from Brazil and Mexico. The new OEM agreement with Stellantis, while contributing to subscriber growth, involves lower ARPU compared to the company's average. Increased R&D and marketing expenditures outpaced revenue growth, raising concerns about cost management. CapEx was higher than average in Q1, with expectations for it to decrease in subsequent quarters, indicating potential volatility in capital expenditures. The insurance market in Latin America, particularly in Brazil and Mexico, shows limited short-term potential for usage-based insurance (UBI) solutions, impacting growth opportunities in this segment. Q: In terms of new agreements, does it imply you set up new equipment and provide services for each produced car by Stellantis in Latin America, or do you have some options for them? A: Eyal Sheratzky, Co-CEO, explained that the current agreement with Stellantis is to provide services based on existing technology in their cars. While there is potential to broaden the relationship and add other services or hardware in the future, the current focus is on service provision. Q: What primarily affected the ramp-up of your subscription base, given the recent increase to roughly 100,000 per quarter? A: Eyal Sheratzky noted that the agreement with Stellantis initially brought a bulk of car owners to Ituran, which is not typical. Future quarters are expected to return to the usual rate of about 40,000 new subscribers per quarter. Q: Has Ituran taken steps to improve product gross margins, and what should we expect for the next couple of quarters? A: Eli Kamer, CFO, stated that the improvement in gross margins is due to operational leverage and cost savings. While telematics services margins are expected to improve with subscriber growth, product margins may fluctuate due to product mix changes. Q: What are your expectations for the Latin American insurance market, particularly regarding UBI insurance? A: Eyal Sheratzky mentioned that while there is high demand for car theft solutions in Brazil, the insurance companies in Brazil and Mexico are not yet ready to adopt UBI solutions. However, Argentina has shown some interest, and Ituran is prepared to capitalize on future opportunities. Q: Can you discuss the dynamics in the market for product revenues and how you see the pipeline evolving throughout the year? A: Eli Kamer explained that product revenue pipelines are managed on a daily basis, with stock levels adjusted according to demand. Gross margins for product revenues are expected to remain around 20-25%, depending on the product mix. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Bloomberg
2 hours ago
- Bloomberg
Goldman CIO Service Suddenly Catches On in Japan After 10 Years
It took a more than a decade of trying, but Goldman Sachs Group Inc. last year landed the first client for its business of helping institutions manage their money in Japan. A second pension signed up in early 2025. Now about 10 more potential customers are in the pipeline, according to Kenro Tsutsumi, head of Goldman Sachs Asset Management Japan.
